Q BioMed, Inc's (OTCQB: QBIO) Denis Corin presents to investors at the Proactive One2One Virtual Conference.
Q BioMed is a biotech acceleration and commercial stage company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector.
Price: 1.08 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has received a US patent for its Uttrocide-B molecule as a potential liver cancer treatment. Corin says the company now has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology,...
Retail & consumer
